Clinical trial
Cardiovascular Protective Effect of Spironolactone in Hemodialysis
NCT00277693 · Universidad de los Andes, Chile, Other · Unknown status
Key facts
| NCT number | NCT00277693 |
|---|---|
| Title | Cardiovascular Protective Effect of Spironolactone in Hemodialysis |
| Official title | Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies |
| Lead sponsor | Universidad de los Andes, Chile, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hemodialysis |
| Intervention type | Drug |
| Interventions | Spironolactone (drug) |
| First posted | Jan 16, 2006 |
| Last update posted | Jan 16, 2006 |
| Countries | Chile |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: